Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

PET uncovers abnormal tau deposits associated with CTE in live subjects May enable diagnosis of CTE in living people one day

DOE transfers land to Coquí Pharma for isotope production facility Will be used primarily to produce Mo-99

Amyloid PET scans help with Alzheimer's clinical management New insights from the 11,000 patient IDEAS study

United Imaging's total-body PET scanner shows promise in four new studies Faster scans, lower dose and 'a level of detail never seen in PET'

NorthStar buys IBA electron accelerators for Mo-99 production Will increase production capacity and efficiencies

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Researchers call on FDA to address gadolinium safety concerns

by Lauren Dubinsky , Senior Reporter
The FDA needs to conduct more studies evaluating the adverse health effects of gadolinium exposure and the scientific community has to work on developing treatments for gadolinium toxicity, according to a literature review published yesterday in the Springer journal, BioMetals.

“Unfortunately we don't yet know of any test that can be used to determine the level of toxicity that may result from gadolinium exposure,” Moshe Rogosnitzky, lead author of the article, told HCB News. “Some of the studies we reviewed did show a higher risk of accumulation in patients with elevated zinc levels, through a process known as transmetallation.”

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Researchers from MedInsight Research Institute and Israel’s Ariel University reviewed various studies and didn’t find any drugs that were shown to be effective at rapidly removing gadolinium from a patient’s body.

One of the studies revealed that it may take up to 156 years to remove gadolinium stored inside the body using a certain drug. Rogosnitzky thinks that the existing drugs that are used for other metal toxicities should be evaluated to determine if they can be used to detect gadolinium accumulation.

Rogosnitzky and his colleagues have observed elevated gadolinium levels in the blood or urine of patients many months after they underwent MR scans with gadolinium-based contrast agents (GBCAs). In July 2015, the FDA announced that it was evaluating the risk of brain-deposits in patients who undergo repeated exposure to GBCAs.

In order to make it a standard practice to measure gadolinium toxicity, Rogosnitzky thinks that a retrospective study needs to be conducted. The study should measure blood or urine levels of gadolinium in patients without kidney diseases who have undergone MR using GBCAs in the past six months, according to the review.

“This test is available at several labs including the Mayo Clinic,” Rogosnitzky said. “We should then try to correlate the gadolinium levels with any new symptoms these patients may have developed in recent months.”

Dr. Emanuel Kanal, an expert on gadolinium and MR safety, and a professor of radiology and the director of MR services at the University of Pittsburgh Medical Center, recently told HCB News that there is probably no agent completely immune to having some retention in the body.

“But there are significant differences in the amount or rate that they accumulate in a human after a certain number of doses of these agents," Kanal added, while also emphasizing that we still have no scientific evidence regarding the medical consequences of accumulation.
  Pages: 1 - 2 >>

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.